The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer

Abstract

Introduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health.